EQS-News: Evotec enters partnership with Hannover Medical School to create molecular patient database in autoimmune diseases
Retrieved on:
Friday, October 28, 2022
Therapy, Metabolomics, Company, Biotechnology, Drug development, Frankfurt Stock Exchange, ESG, LinkedIn, MDAX, NASDAQ, Safety, Diagnosis, Disease, MHH, Communication, Multiomics, Department, ISIN, University, Neurology, B cell, Genomics, Database, Patient, EVO, Proteomics, Degenerative disease, Immunology, SLE, Research, News, Sickle Cell Anemia, a Molecular Disease, Twitter, Hannover Medical School, Lupus, Science, RESIST, SJS, Partnership, Security (finance), Pharmaceutical industry, Medical imaging, Medical device, Rheumatology, Evotec
Together with supplementary pseudonymised patient data, these PanOmics data will feed into Evotecs proprietary translational molecular patient data platform E.MPD, which serves as the central data repository for molecular patient data.
Key Points:
- Together with supplementary pseudonymised patient data, these PanOmics data will feed into Evotecs proprietary translational molecular patient data platform E.MPD, which serves as the central data repository for molecular patient data.
- Evotec has the exclusive right to exploit the data commercially with its unique capabilities in the field of data-driven precision medicine.
- Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: We are excited to enter this partnership with MHH and expand Evotecs E.MPD database into autoimmune diseases.
- E.MPD, Evotecs translational molecular patient database, is one of the largest and highest quality molecular databases globally.